- Senior Vice President at Fresenius Kabi, currently heading the Intelligent Automation & Artificial Intelligence department.
- Inspirational Leader with track record in establishing innovative transformational topics through high performing teams. Authentic, passionate and curious personality with strong networking capabilities.
- Successfully build up the Global Business Services and Internal Control System (ICS) organization from scratch in decentral setup and lead it, broad experience in Finance Function, Digital Transformation, Change, Program Management (PMO), Cost excellence and General Management as direct report to the CEO.
- Experienced M&A Frankfurt and London (PWC), Certified Chartered Accountant (ACCA), studied business in Barcelona and Treves, participated in the Fresenius Top Executive program with Harvard Business school and Artificial Intelligence program with MIT.
- Married, two daughters, long distance runner and engaged in the family wine business.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.